{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T13:12:24Z","timestamp":1775567544109,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to systematically review recent economic evaluations of elbasvir\/grazoprevir (EBR\/GZR) for chronic hepatitis C (CHC), to critically appraise the reporting quality and to summarize the results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A literature search was undertaken using Medline, Embase, the Cochrane Library, EconLit, China National Knowledge Infrastructure, Wanfang Data, and Chongqing VIP to identify original articles containing economic evaluations of EBR\/GZR for CHC published between 1 January 2000 and 31 December 2020. The Consolidated Health Economic Evaluation Reporting Standards statement was used to assess the quality of reporting of the articles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 93 articles identified, 13 studies fulfilled the inclusion criteria. These studies were conducted in 4 countries, and 8 active interventions were assessed. The target population was patients infected with CHC genotype 1 infection in all studies. Eight out of 13 studies that compared EBR\/GZR vs. other direct antiviral agents suggested that EBR\/GZR was generally more cost-effective or dominant than daclatasvir\/asunaprevir (DCV\/ASV), sofosbuvir\/velpatasvir (SOF\/VEL), ledipasvir\/sofosbuvir (LDV\/SOF), ombitasvir\/paritaprevir\/ritonavir + dasabuvir (3D) but not more cost-effective than glecaprevir\/pibrentasvir (GLE\/PIB). Two studies from China and one study from the USA that compared EBR\/GZR vs. pegylated interferon and ribavirin (PegIFN\/RBV) consistently indicated that EBR\/GZR was generally more cost-effective than PegIFN\/RBV. One study from Italy compared EBR\/GZR with SOF + PegIFN\/RBV and suggested that EBR\/GZR had a lower cost and higher effectiveness. One study from France and one study from the USA confirmed that compared with non-therapy for patients with chronic kidney disease, EBR\/GZR was cost-effective at commonly accepted current standards. All included studies were of good quality of reporting, with an average score of 21.9 (range 19\u201323).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>EBR\/GZR for CHC genotype 1 might be cost-effective or dominant compared with PegIFN\/RBV and other direct antiviral agents (SOF\/VEL, 3D, DCV\/ASV, LDF\/SOF) or non-therapy. However, under certain assumptions, EBR\/GZR was not a cost-effective alternative for CHC patients vs. GLE\/PIB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2022.836986","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:07:54Z","timestamp":1652429274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Elbasvir\/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review"],"prefix":"10.3389","volume":"10","author":[{"given":"Jinyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruxu","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology."},{"key":"B2","unstructured":"Hepatitis C2021"},{"key":"B3","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3760\/cma.j.issn.1007-3418.2019.12.008","article-title":"Guidelines for the prevention and treatment of hepatitis C(2019 version)","volume":"27","year":"2019","journal-title":"Chin J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/jgh.12398","article-title":"Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection","volume":"29","author":"Rao","year":"2014","journal-title":"J Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12985-017-0710-z","article-title":"Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution","volume":"14","author":"Zhang","year":"2017","journal-title":"Virol J."},{"key":"B7","first-page":"5","article-title":"Value assessment of elbasvir\/grazoprevir in the treatment of chronic virus hepatitis C","volume":"15","author":"Yin","year":"2020","journal-title":"China J Pharm Econ."},{"key":"B8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/13696998.2020.1737534","article-title":"Economic burden of needlestick injuries among healthcare workers in China","volume":"23","author":"Zhang","year":"2020","journal-title":"J Med Econ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-Term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/liv.13335","article-title":"Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study)","volume":"37","author":"Sulkowski","year":"2017","journal-title":"Liver Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1015239","DOI":"10.1155\/2018\/1015239","article-title":"Cost effectiveness of bosentan for pulmonary arterial hypertension: a systematic review","volume":"2018","author":"You","year":"2018","journal-title":"Can Respir J."},{"key":"B13","unstructured":"Highlights of Prescribing Information2019"},{"key":"B14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40273-013-0032-y","article-title":"Consolidated health economic evaluation reporting standards (CHEERS) statement","volume":"31","author":"Husereau","year":"2013","journal-title":"Pharmacoeconomics."},{"key":"B15","unstructured":"CCEMG-EPPI-Centre Cost Converter2019"},{"key":"B16","first-page":"470","article-title":"Cost-effectiveness analysis of elbasvir\/grazoprevir for the treatment of chronic hepatitis C","volume":"29","author":"Chen","year":"2020","journal-title":"Chin J New Drugs."},{"key":"B17","first-page":"1113","article-title":"Cost-effectiveness analysis of glecaprevir\/pibrentasvir versus elbasvir\/grazoprevir in chronic hepatitis C genotype 1b treatment-naive patients without cirrhosis","volume":"31","author":"Chen","year":"2020","journal-title":"China Pharm"},{"key":"B18","first-page":"14","article-title":"Cost-Effectiveness analysis of elbasvir\/grazoprevir and sofosbuvir\/velpatasvir in the treatment of hepatitis C","volume":"14","author":"Chen","year":"2019","journal-title":"China J Pharm Econ."},{"key":"B19","first-page":"1352","article-title":"Elbasvir\/grazoprevir for patients with chronic hepatitis C virus genotype 1b infection in China: an economic evaluation","volume":"18","author":"Chen","year":"2018","journal-title":"Chin J Evid Based Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10620-020-06281-8","article-title":"Cost-Utility of all-oral direct-acting antiviral regimens for the treatment of genotype 1 chronic hepatitis c virus-infected patients in Hong Kong","volume":"66","author":"Yuen","year":"2021","journal-title":"Dig Dis Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e035224","DOI":"10.1136\/bmjopen-2019-035224","article-title":"Cost-utility of sofosbuvir\/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China","volume":"10","author":"Yun","year":"2020","journal-title":"BMJ Open."},{"key":"B22","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12325-019-01166-3","article-title":"A cost-effectiveness analysis of glecaprevir\/pibrentasvir versus existing direct-acting antivirals to treat chronic hepatitis C in Japan","volume":"37","author":"Kawaguchi","year":"2020","journal-title":"Adv Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40261-018-0702-9","article-title":"Cost-Effectiveness of elbasvir\/grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China","volume":"38","author":"Chen","year":"2018","journal-title":"Clin Drug Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0194329","DOI":"10.1371\/journal.pone.0194329","article-title":"Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France","volume":"13","author":"Maunoury","year":"2018","journal-title":"PLoS ONE."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s10198-018-0980-4","article-title":"Economic evaluation of zepatier for the management of HCV in the Italian scenario","volume":"19","author":"Rolli","year":"2018","journal-title":"Eur J Health Econ."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jval.2017.05.003","article-title":"Cost-Utility of elbasvir\/grazoprevir in patients with chronic hepatitis c genotype 1 infection","volume":"20","author":"Corman","year":"2017","journal-title":"Value Health."},{"key":"B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jvh.12639","article-title":"Cost-effectiveness of elbasvir\/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States","volume":"24","author":"Elbasha","year":"2017","journal-title":"J Viral Hepat."},{"key":"B28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/apt.13882","article-title":"The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-na\u00efve and treatment-experienced) subjects treated with all-oral elbasvir\/grazoprevir regimens in the United States","volume":"45","author":"Elbasha","year":"2017","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.836986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T08:08:02Z","timestamp":1652429282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.836986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":28,"alternative-id":["10.3389\/fpubh.2022.836986"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.836986","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"article-number":"836986"}}